UBS 2026 CEO Call Series
Logotype for Thermo Fisher Scientific Inc

Thermo Fisher Scientific (TMO) UBS 2026 CEO Call Series summary

Event summary combining transcript, slides, and related documents.

Logotype for Thermo Fisher Scientific Inc

UBS 2026 CEO Call Series summary

19 Nov, 2026

Market conditions and outlook

  • Q3 performance was ahead of expectations; outlook was raised during 2026, with strategy driving growth, share gains and stronger financial results.

  • End markets became more predictable; pharma and biotech strengthened, biotech funding improved, and academic and government markets stabilized.

  • End markets are expected to keep strengthening and return to normal long-term growth by 2028.

  • Split government and bipartisan congressional support for NIH were viewed as constructive; academic spending could return to growth in 2027.

  • Reshoring commitments remain intact, supported by the logic of producing closer to markets and industry profits.

Pharma, biotech and academic markets

  • Pharma and biotech grew at a high-single-digit rate in Q3; the recovery is underway, with pharma R&D investment and biotech customer confidence strengthening.

  • Biotech spending remains weighted toward later-stage development; early research is expected to pick up as companies refill pipelines, with early signs in lab supplies.

  • AI is adding to pharma and biotech R&D investment expectations through the potential for higher returns on research spending.

  • Academic and government markets were flat in Q3 and expected to decline slightly for 2026; recovery toward low-single-digit growth is expected over the next couple of years.

  • China represents 7.5% of revenue; recent low-double-digit growth was led by pharma, biotech and semiconductor demand, and could be an upside over the next couple of years.

Business performance and initiatives

  • Bioproduction has strong positions in cell culture media, single-use technologies and purification; longer-term growth is expected at high single digits to low double digits, after tougher comparisons in coming quarters.

  • Biosciences and genetic sciences face softer academic and early biotech markets; improvement is expected as 2027 progresses, with growth strengthening meaningfully.

  • Analytical Instruments grew mid-single digits in Q3, led by electron microscopy, chromatography and mass spectrometry; the new Orbitrap launched to strong demand.

  • PreCure, formed with Mayo Clinic, will analyze more than one million biological samples to identify disease signals before symptoms appear.

  • Pharma services is expected to deliver a strong year; reshoring contracts support U.S. medicine production, while Accelerator Drug Development capabilities help customers bring medicines to market faster.

  • Clinical research revenue grew mid-single digits; long-term growth is expected at mid- to high-single digits, with authorizations and new wins exceeding revenue.

  • Clario integration was off to a good start around seven to eight months after closing; technology investment supports an AI-enabled clinical development platform expected to become a high-growth, highly profitable business.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Thermo Fisher Scientific